New Directors to the Board, page-26

This is a positive sign UNS is focusing on what works and cost reduction, rather than expanding blindly. November 2 is the presentation in USA. It should move the sp in an upward direction if they can cease to concentrate on dud activities and push to the model that is generating income.

They have some solid contracts with Amgen and sanofi. Lets hope they can push forward and bring the sp where it should be like in the old days.

eitherway, I will be accumulating as I dont see this too much risk.

GLTA